MENU
+Compare
VIVS
Stock ticker: NASDAQ
AS OF
May 2 closing price
Price
$2.00
Change
+$0.03 (+1.52%)
Capitalization
3.6M

VIVS VivoSim Lab Inc Forecast, Technical & Fundamental Analysis

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data... Show more

Industry: #Biotechnology
VIVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for VIVS with price predictions
May 02, 2025

VIVS sees its Stochastic Oscillator ascending out of oversold territory

On April 30, 2025, the Stochastic Oscillator for VIVS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 66 instances where the indicator left the oversold zone. In of the 66 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 28, 2025. You may want to consider a long position or call options on VIVS as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VIVS advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for VIVS moved out of overbought territory on March 27, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for VIVS turned negative on April 07, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for VIVS entered a downward trend on April 30, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VIVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.891) is normal, around the industry mean (14.232). P/E Ratio (0.000) is within average values for comparable stocks, (64.218). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.855). Dividend Yield (0.000) settles around the average of (0.023) among similar stocks. P/S Ratio (20.747) is also within normal values, averaging (252.894).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
VIVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

VIVS is expected to report earnings to -227 cents per share on May 22

VivoSim Lab Inc VIVS Stock Earnings Reports
Q1'25
Est.
$-2.28
Q4'24
Missed
by $2.04
The last earnings report on February 28 showed earnings per share of -228 cents, missing the estimate of -25 cents. With 171.94K shares outstanding, the current market capitalization sits at 3.60M.
A.I. Advisor
published General Information

General Information

a company which engages in developing and commercializing functional human tissues

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PLAY19.290.57
+3.04%
Dave & Buster's Entertainment
SBS19.920.54
+2.76%
Companhia DE Saneamento B Sico DO Estado DE SAO Paulo-Sabesp Ads's
UVSP30.520.79
+2.66%
Univest Financial Corp
TOI2.800.01
+0.36%
Oncology Institute (The)
LIXT1.25-0.01
-0.79%
Lixte Biotechnology Holdings

VIVS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VIVS has been loosely correlated with GLTO. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VIVS jumps, then GLTO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIVS
1D Price
Change %
VIVS100%
+1.52%
GLTO - VIVS
38%
Loosely correlated
-0.33%
ORMP - VIVS
37%
Loosely correlated
+2.20%
ACET - VIVS
27%
Poorly correlated
+6.60%
KRRO - VIVS
26%
Poorly correlated
+13.81%
SLNO - VIVS
26%
Poorly correlated
+0.28%
More